https://www.avient.com/sites/default/files/2025-05/AVNT Q1 2025 Webcast Slides_w_non-GAAP.pdf
Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. Each of such adjustments has not yet occurred, are out of Avient’s control and/or cannot be reasonably predicted. Slide 12 Slide 13: Avient 2024 sales Slide 14: Color, Additives & Inks Slide 15: Specialty Engineered Materials Slide 16: Avient 2024 regional sales, by end market Slide 17: Raw material basket IR Deck - AVNT-2025.03.31 Non-Gaap Recs.pdf Attachment
https://www.avient.com/sites/default/files/2025-05/AVNT Q1 2025 webcast slides_v17.pdf
Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. Each of such adjustments has not yet occurred, are out of Avient’s control and/or cannot be reasonably predicted. For the same reasons, Avient is unable to address the probable significance of the unavailable information. 3Copyright © .
https://www.avient.com/sites/default/files/resources/Resilience%2520LS%2520Diffuse%2520Comparison%2520Guide_No%2520CP.pdf
You have the responsibility to conduct full-scale end-product performance testing to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product.
https://www.avient.com/sites/default/files/resources/Investor%2520Day%2520-%2520May%25202012%2520-%2520Critical%2520Imperatives.pdf
Page 102 Critical Imperatives – Medium to Long Term • Continue cultural and paradigm shift from commodity compounder to collaborative formulator as One PolyOne • Accelerate innovation and leverage megatrends to improve our mix of business with higher-margin improve our mix of business with higher-margin specialty products • Increase specialty contribution and advance globalization via acquisitions • Drive relentless execution and creative innovation as key competitive differentiators Page 103 2011 Proforma ColorMatrix 2015 Target “Where we are” “Where we expect to be” 1) Operating Income % Specialty 8.9% PP&S 7.2% 12 – 16% 9 – 12% Elevating our Expectations and Yours PP&S 7.2% Distribution 5.6% 2) Specialty Platform % of Operating Income 50% 3) ROIC* (after-tax) 10% 4) Adjusted Annual EPS Growth 3 yr CAGR = 71% 9 – 12% 6 – 7.5% 65 – 75% 15% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 104
https://www.avient.com/sites/default/files/2024-03/Terms and Conditions of Sale for South Africa.pdf
TERMS AND CONDITIONS These Terms and Conditions govern the sale of Products to another (“Buyer”) by Avient Corporation and its affiliates (“Seller”). 1. The arbitration shall be conducted before an arbitrator jointly appointed by the parties. The arbitration shall be conducted in English and in accordance with the rules of the Arbitration Foundation of South Africa.
https://www.avient.com/sites/default/files/2020-08/2020-hammerhead-application-install-guide.pdf
Contact Avient for more information. FASTENER SELECTION Copyright © 2020, Avient Corporation. To learn more about Avient’s advanced composite solutions, contact Avient at +1.844.4AVIENT www.avient.com
https://www.avient.com/sites/default/files/2023-12/Polystrand Thermoplastic Composite Panel Application _ Install Guide.pdf
Contact Avient for more information. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. You have the responsibility to conduct full-scale end-product performance testing to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product.
https://www.avient.com/sites/default/files/2021-12/Chemically Resistant Materials Whitepaper.pdf
In this study, Avient’s Trilliant™ HC8900 and Edgetek™ ET8900 thermoplastics were tested alongside competitive materials used for various medical and consumer device enclosures. - - 8© 2021 Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 Table 3B. While the method used in this study is useful for providing comparative data, it should be noted that the testing is conducted under a single strain condition with the disinfectant applied in a manner intended to accelerate ESC behavior; the strain and exposure conditions based on actual use scenarios should always be tested to confirm the anticipated performance in the field.
https://www.avient.com/sites/default/files/resources/HIGH_PERFORMANCE_CLEAR_THERMOPLASTICS_ELASTOMER.pdf
SBC compounds offer good economics and formulation flexibility meeting the end use performance requirements. Formulation Development Based on the market feedback, the developmental TPE needed to meets three major general requirements;, clarity, heat resistance and softness.
https://www.avient.com/sites/default/files/2022-08/Environmental Stress Cracking Resistance _ESCR_ Design Guide %281%29.pdf
ESCR Design Guide 6 FIGURE 17 - Non-structural hole design guidelines 1.844.4AVIENT www.avient.com Copyright © 2022, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. You have the responsibility to conduct full-scale end-product performance testing to determine suitability in your application, and you assume all risk and liability arising from your use of the information and/or use or handling of any product.